Exploring how gene deletions in cancer can create new treatment opportunities
Bystander gene deletions in cancer: mechanisms of therapeutic opportunities and challenges
This study is looking at how certain gene deletions in cancer cells can create weaknesses that we might be able to target with new treatments, especially for tough cancers like glioblastoma, to help improve outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11220977 on NIH RePORTER |
What this research studies
This research investigates the impact of bystander gene deletions in cancer, which occur when nearby genes are unintentionally deleted alongside key tumor suppressor genes. By understanding these deletions, the research aims to identify unique vulnerabilities in cancer cells that could be targeted with specific therapies. The approach involves analyzing the effects of these deletions on cell growth and survival, particularly in cancers like glioblastoma where traditional therapies have failed. The goal is to uncover new therapeutic strategies that leverage these vulnerabilities to improve treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit specific gene deletions, particularly those who have not responded to conventional therapies.
Not a fit: Patients whose cancers do not involve significant bystander gene deletions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that are more effective for certain cancer patients.
How similar studies have performed: While the concept of targeting bystander gene deletions is relatively novel, similar approaches in cancer therapy have shown promise in other contexts.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Dasgupta, Biplab — Emory University
- Study coordinator: Dasgupta, Biplab
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.